As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Portfolio Pulse from Vandana Singh
Neurocrine Biosciences' Phase 2 study data for its schizophrenia treatment NBI-1117568 showed a statistically significant but lower-than-expected effect size compared to competitors. This led to a significant drop in NBIX's stock price.
August 28, 2024 | 3:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Neurocrine Biosciences' Phase 2 study for NBI-1117568 showed a statistically significant reduction in PANSS scores, but the effect size was lower than competitors, leading to an 18.9% drop in stock price.
The study results showed a statistically significant reduction in symptoms, but the effect size was lower than competitors, leading to a significant drop in stock price as investors were disappointed.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
AbbVie's emraclidine showed a higher effect size in previous studies compared to Neurocrine's NBI-1117568, which may strengthen ABBV's competitive position in the schizophrenia treatment market.
ABBV's emraclidine demonstrated a higher effect size in previous studies, which could enhance its competitive position in the market compared to NBIX's recent results.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Bristol Myers Squibb's acquired Karuna's KarXT showed a higher effect size in previous studies compared to Neurocrine's NBI-1117568, potentially positioning BMY favorably in the schizophrenia treatment market.
BMY's KarXT demonstrated a higher effect size in previous studies, which could enhance its competitive position in the market compared to NBIX's recent results.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 50